THE WHAT? OliX Pharmaceuticals has raised approximately KRW 110 billion through a strategic investment from BOLD, L’Oréal’s corporate venture capital fund, and U.S.-based Weiss Asset Management.
THE DETAILS The South Korean biotechnology company secured the funding through a third-party allotment of newly issued common shares. BOLD, which invests in beauty, biotech and technology companies with disruptive innovation potential, participated alongside existing investor Weiss Asset Management, which previously invested in OliX in 2025. OliX plans to use the proceeds to advance its RNA interference (RNAi) therapeutic pipeline, including projects focused on skin and hair applications. The investment also strengthens the company’s existing partnership with L’Oréal, combining OliX’s small interfering RNA (siRNA) platform with L’Oréal’s expertise in biology, formulation science and beauty innovation. The companies said the collaboration aims to accelerate the development of next-generation beauty and wellness solutions backed by advanced biological research.
THE WHY? The investment highlights growing interest in biotechnology-driven beauty innovation and provides OliX with additional resources to expand its research capabilities while deepening its strategic relationship with one of the world’s largest beauty companies.
Source: business wire
